Literature DB >> 16415380

Adalimumab for treatment of cutaneous sarcoidosis.

Michael P Heffernan1, David I Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16415380     DOI： 10.1001/archderm.142.1.17

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN： 0003-987X


× No keyword cloud information.
  14 in total

Review 1.  Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.

Authors:  D E Furst; F C Breedveld; J R Kalden; J S Smolen; G R Burmester; J Sieper; P Emery; E C Keystone; M H Schiff; P Mease; P L C M van Riel; R Fleischmann; M H Weisman; M E Weinblatt
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

2.  Steroid-unresponsive neurosarcoidosis successfully treated with adalimumab.

Authors:  Michael Marnane; Timothy Lynch; Jaqueline Scott; John Stack; Peter J Kelly
Journal:  J Neurol       Date:  2009-01-31       Impact factor: 4.849

Review 3.  Cytokine modulators in the treatment of sarcoidosis.

Authors:  E Bargagli; C Olivieri; P Rottoli
Journal:  Rheumatol Int       Date:  2011-06-05       Impact factor: 2.631

4.  Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report.

Authors:  Supen R Patel
Journal:  J Med Case Rep       Date:  2009-07-29

Review 5.  [Systemic psoriasis therapy - the next step. Adalimumab].

Authors:  G Wozel; M Sticherling
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

6.  Neuro-ophthalmologic Manifestations of Sarcoidosis.

Authors:  Barney J Stern; James Corbett
Journal:  Curr Treat Options Neurol       Date:  2007-01       Impact factor: 3.598

Review 7.  Evidence-based therapy for cutaneous sarcoidosis.

Authors:  Christy B Doherty; Ted Rosen
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 8.  Adalimumab in dermatology.

Authors:  Pawel Traczewski; Lidia Rudnicka
Journal:  Br J Clin Pharmacol       Date:  2008-07-11       Impact factor: 4.335

9.  Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines.

Authors:  Robert P Baughman; Keith C Meyer; Ian Nathanson; Luis Angel; Sangeeta M Bhorade; Kevin M Chan; Daniel Culver; Christopher G Harrod; Mary S Hayney; Kristen B Highland; Andrew H Limper; Herbert Patrick; Charlie Strange; Timothy Whelan
Journal:  Chest       Date:  2012-11       Impact factor: 9.410

10.  Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis.

Authors:  José Luis Callejas-Rubio; Lourdes López-Pérez; Norberto Ortego-Centeno
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.